Management of Dysphagia in HIV-Positive Patients

Clinical Assessment

The Centers for Disease Control and Prevention recommends that HIV-positive patients with mild odynophagia and weight loss be treated with empiric antifungal therapy for presumed Candida esophagitis, while continuing antiretroviral therapy and monitoring nutritional status 1
Patients with HIV may present with mild pain when swallowing (odynophagia) 2
Weight loss of 5 pounds or more in HIV patients can occur at any stage of disease, even with relatively preserved immune function 3
A current CD4 count of 558 cells/μL indicates relatively preserved immune function, but does not exclude the possibility of opportunistic infections 4

The American College of Radiology suggests that infectious esophagitis is a major consideration in HIV-positive patients with dysphagia or odynophagia, most commonly due to Candida albicans 2
Other common causes of esophagitis in HIV-positive patients include herpes simplex virus, cytomegalovirus, and idiopathic ulcers 2

The Centers for Disease Control and Prevention recommends empiric antifungal therapy with fluconazole for presumed Candida esophagitis in HIV-positive patients with dysphagia or odynophagia 1
The typical regimen for fluconazole is 200 mg on day 1, followed by 100 mg daily for 14 days 1
If symptoms persist after 3-5 days of empiric antifungal therapy, diagnostic evaluation should be initiated 2

The American College of Nutrition recommends that nutritional counseling be initiated immediately to address weight loss in HIV-positive patients 3
Protein intake should achieve 1.2 g/kg body weight/day in stable phases of HIV disease 3
Oral nutritional supplements may be considered if oral intake remains inadequate despite counseling 3
Tube feeding may be indicated for patients with dysphagia where oral supplements are not effective 3

Symptoms should be reassessed after 3-5 days of antifungal therapy 1
Weight should be monitored weekly during acute management 3
If weight loss continues despite treatment, potential causes such as depression, medication side effects, other concurrent infections, and malignancy should be considered 1, 3

Empiric treatment should not be delayed while waiting for diagnostic studies in a symptomatic HIV-positive patient with dysphagia or odynophagia 2
Normal oral mucosa does not exclude esophageal disease 1
Nutritional support is an essential component of management and should not be overlooked 3
Medication adherence and potential drug interactions that might affect antiretroviral efficacy should be assessed 5